You are here

Formulation of LbL microparticle vaccine in microneedle array for intradermal del

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI109811-01
Agency Tracking Number: R43AI109811
Amount: $110,923.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
5 Science Park, 3rd Floor
NEW HAVEN, CT 06511-1989
United States
DUNS: 361522811
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 THOMAS POWELL
 (203) 772-3430
 jpowell@artificialcelltech.com
Business Contact
 DONALD MASTERS
Phone: (203) 772-3430
Email: dmasters@artificialcelltech.com
Research Institution
 Stub
Abstract

Abstract The ability of the immune system to recognize and initiate an immune response to foreign particles such as bacteria and viruses has generated interest in development of particulate vaccine technologies. We are developing an innovative approach toproduce particulate vaccines via layer-by-layer (LbL) fabrication of synthetic microparticles (MP). We have shown that LbL-MP loaded with epitopes from respiratory syncytial virus (RSV) or Plasmodium falciparum (Pf) elicit potent and balanced humoral and cellular immune responses that protect the immunized host from infection and disease following pathogen challenge. The LbL-MP vaccines are immunogenic and efficacious when administered at low doses (1-10 g) in aqueous suspension without any exogenous adjuvant, thus offering safety advantages over competing vaccine technologies. In this Phase I feasibility study, we will improve the LbL-MP technology by loading the MP into microneedle arrays designed to deliver the payload directly into the skin, a rich res

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government